SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
SEARCH INTERVENTION REDUCES MORTALITY AT A POPULATION LEVEL IN MEN WITH LOW CD4 COUNT (ABSTRACT
138)
Moses R. Kamya
Makerere University College of Health Sciences, Kampala, Uganda
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS (ABSTRACT
139)
Susan Swindells
University of Nebraska Medical Center, Omaha, NE, USA
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS (ABSTRACT
140)
Chloe Orkin
Barts Health NHS Trust, London, United Kingdom
SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR (ABSTRACT
141)
Jennifer E Sager
Gilead Sciences, Foster City, CA, USA
A PHASE IIA STUDY OF NOVEL MATURATION INHIBITOR GSK2838232 IN HIV PATIENTS (ABSTRACT
142)
Edwin DeJesus
Orlando Immunology Center, Orlando, FL, USA
SYSTEMATIC DETERMINATION OF IN VITRO HIV-1 INTEGRASE RESISTANCE FROM CLINICAL SAMPLES (ABSTRACT
143)
Aniqa Shahid
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
DTG VS LPV/R (DAWNING): EFFICACY BY BASELINE NRTI RESISTANCE AND SECOND-LINE NRTI USE (ABSTRACT
144)
Dannae Brown
ViiV Healthcare, Surry Hills, NSW, Australia
THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS (ABSTRACT
145)
Kathryn E. Stephenson
Beth Israel Deaconess Medical Center, Boston, MA, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
